(Q43614306)

English

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

scientific article published in May 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alessandro Isidori

object named as

A Isidori

10

0 references

author name string

G Visani

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

D Milligan

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

F Leoni

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

J Chang

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

S Kelsey

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

R Marcus

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

R Powles

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

S Schey

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Covelli

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Litchman

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

P P Piccaluga

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

H Mayer

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Malagola

14

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C Pfister

15

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

764-771

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402117

0 references

Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Isolation and expression of a complementary DNA that confers multidrug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of a multidrug resistance gene in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidrug resistance in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of P-glycoprotein expression in haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

P-glycoprotein in Adult Hematologic Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

MDR1 gene expression and treatment outcome in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclosporins as drug resistance modifiers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402117

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402117

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43614306&oldid=2101902879"